JP2004292418A - Method for supplying gamma-linolenic acid by transdermal pathway - Google Patents

Method for supplying gamma-linolenic acid by transdermal pathway Download PDF

Info

Publication number
JP2004292418A
JP2004292418A JP2003124569A JP2003124569A JP2004292418A JP 2004292418 A JP2004292418 A JP 2004292418A JP 2003124569 A JP2003124569 A JP 2003124569A JP 2003124569 A JP2003124569 A JP 2003124569A JP 2004292418 A JP2004292418 A JP 2004292418A
Authority
JP
Japan
Prior art keywords
linolenic acid
acid
gamma
added
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003124569A
Other languages
Japanese (ja)
Inventor
Norinaga Fujishige
昇永 藤重
Kikyo Go
貴郷 呉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2003124569A priority Critical patent/JP2004292418A/en
Publication of JP2004292418A publication Critical patent/JP2004292418A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for the preparation and use of constituent elements for skin care, effective for supplying γ-linolenic acid, linoleic acid as a precursor of the γ-linolenic acid or their mixture through a transdermal pathway for solving the troubles near the epidermis such as dry skin, eczema and tumor caused by the deficiency of γ-linolenic acid. <P>SOLUTION: Refined palm oil or refined horse oil is used as a base, a proper amount of oleic acid is added to the base to adjust the melting point of the composition, γ-linolenic acid is added in an amount of 2-10 pts. based on 10 pts. of the oleic acid, and vitamin E is added in an amount of 0.5-20% based on the γ-linolenic acid to obtain a stabilized constituent element containing γ-linolenic acid. The prepared constituent component is served to practical use by filling in an aluminum-coated tube to shield the component from the influence of oxygen in air and light during storage. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は,ガンマ・リノレン酸が不足することによって生じる乾燥肌や湿疹,腫瘍など表皮近傍のトラブルに対処するため経皮経路を利用してガンマ・リノレン酸やこれの前駆体であるリノール酸あるいはこれらの混合物を補給するスキンケア用の構成要素の調製と利用形態に関する.
【0002】
【従来の技術】
近年,ガンマ・リノレン酸の生体内合成が阻害されていることが原因して糖尿病や心臓疾患,皮膚疾患など発症する例が明らかにされ,これらの治療にガンマ・リノレン酸の経口投与が有効であるとする臨床例が数多く報告されている.
【0003】
【発明が解決しようとする課題】
本発明者は,かねてより皮膚を透過する低分子量成分の挙動に着目し,鋭意研究を重ねて来たが,スキンケアの目的にはガンマ・リノレン酸を経口投与するよりも経皮経路で処置を希望する皮膚の部位近傍にこれを補給する方法が効果的であると考え実験をすすめた結果,本発明を為すに至った.ガンマ・リノレン酸は通常の雰囲気下では空気中の酸素,光,温度に極めて敏感に反応する不安定な化合物であり,このガンマ・リノレン酸が表皮の角質層を透過して生体組織に取り込まれるまでの期間分子構造を安定に維持するための効果的なマトリックスの探索が第一であり,さらにこのガンマ・リノレン酸を含むマトリックスは皮膚表面に塗布されたのちは容易にガンマ・リノレン酸を皮膚表面に向けて放出できる程度の分子間相互作用を保っている事が必要条件となり,本発明の構成要素はこれらの二つの条件を満足するものでなくてはならない.
【0004】
【課題を解決するための手段】
マトリックスの探索には分子設計の観点から人の皮脂の脂肪酸組成に近いものが目標と設定され,塗布された後,皮膚表面でガンマ・リノレン酸を放出するためには弱い分子間力で結晶を形成する飽和脂肪酸が主成分であることが望ましいとして,ミリスチン酸,パルミチン酸,ステアリン酸の混合物を選んだが,これらは室温では結晶状態の固体であり,このままでは皮膚表面に塗布することは容易ではないため,これらの混合組成に対して三分の1から等量程度のオレイン酸を混合することで人の体温近くでは液体状態となるマトリックスの基材を得た.原材料としての入手の容易さを考えると,これらの条件を充たす基材には精製したパームオイルあるいは精製した馬油が挙げられるので,以下の実施例ではこれら精製したパームオイルあるいは馬油を使用している.本発明によれば,マトリックスとして利用するための混合組成の融点の調整は主としてオレイン酸の添加量を加減することで実現する.また,ガンマ・リノレン酸の安定化のためにはビタミンEの添加は有効であるが,酸素との接触,光の影響を避けるために本発明による構成要素はアルミニウムコートされたチューブを容器としてこれに充填した状態で実用に供する.
【0005】
【作用】
従来,経皮経路を利用して薬効成分を補給する例にはサルチル酸メチル製剤や心臓病薬のニトログリセリンの貼り薬,禁煙用のニコチンパッチなどが実用されているが,これらはすべて経皮で透過する薬効成分が毛細血管に吸収されているのに対して,本発明によるガンマ・リノレン酸あるいはこれの前駆体であるリノール酸,あるいはこれらの混合物は飽和脂肪酸を主成分とするマトリックス中に溶解されていて,皮膚の所定の部位に塗布されたあと角質層あるいは表皮層から真皮層にかけて浸透してそこに滞留できればよい.
【0006】
【発明の実施の形態】
本発明を実施するため,構成成分のマトリックスには飽和脂肪酸であるミリスチン酸,パルミチン酸,ステアリン酸あるいはこれらの混合物が用いられる.これらはオレイン酸を添加されて最終的な組成の融点を20℃近傍になるよう調節される.固体状態にあるマトリックス中に置かれたガンマ・リノレン酸あるいはリノール酸の分子運動は制限される結果,安定化が実現されている.
本発明によれば主材であるガンマ・リノレン酸の量はマトリックスの融点の調整に使用するオレイン酸の量10に対して2から10の範囲で添加される.精製したパームオイルをマトリックスとして使用する時はパームオイルに含まれるオレイン酸と融点調整に使用するオレイン酸の総量に対してガンマ・リノレン酸の添加量が2から10の範囲であるよう調節され,オレイン酸と等量までのリノール酸を添加することもできる.馬油は人の皮脂に近い組成をしているので,これをマトリックスとする場合には馬油に含まれるオレイン酸の量を10としてガンマ・リノレン酸の量を2から10の範囲で添加する.通常,馬油にはオレイン酸の量10に対して3から5の量に相当するリノール酸が含まれていてスキンケアに役立っているほか,組成全体の融点降下にも貢献しているがこれにオレイン酸と等量になるまでリノール酸を添加することもできる.本発明によって調製された構成成分はアルミニウムコートしたチューブに充填して実用に供されるが,酸化防止剤であるビタミンEはガンマ・リノレン酸の量に対して0.5%から20%の範囲で添加されていることが望ましい.
【0007】
【発明の効果】
本発明による構成成分を上腕部の皮膚に塗布して,充分に擦込み表面をラップフィルムで被覆して1時間経過後,この部位から油吸取紙を使用して表皮の表面にある油分を回収し,ガスクロマトグラフィーにより含まれる脂肪酸成分を分析して塗布前の成分の脂肪酸組成と比較したところ,ガンマ・リノレン酸の大部分とリノール酸の一部が減少していて経皮でこれらが皮膚組織に吸収された事を示していた.
[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention utilizes a transdermal route to cope with problems near the epidermis such as dry skin, eczema, and tumors caused by a lack of gamma-linolenic acid, and uses gamma-linolenic acid or its precursor linoleic acid or Preparation and application of skin care components to replenish these mixtures.
[0002]
[Prior art]
In recent years, cases of diabetes, heart disease, skin disease, etc. due to inhibition of the in vivo synthesis of gamma-linolenic acid have been clarified, and oral administration of gamma-linolenic acid is effective for these treatments. Many clinical cases have been reported.
[0003]
[Problems to be solved by the invention]
The present inventor has focused on the behavior of low molecular weight components that have penetrated the skin for a long time, and has been conducting intensive studies. However, for the purpose of skin care, gamma linolenic acid is treated by a transdermal route rather than orally. We thought that the method of replenishing it near the desired skin site was effective and proceeded with experiments, which resulted in the present invention. Gamma-linolenic acid is an unstable compound that reacts extremely sensitively to oxygen, light, and temperature in the air under normal atmosphere, and this gamma-linolenic acid penetrates the stratum corneum of the epidermis and is taken into living tissues The search for an effective matrix for maintaining the molecular structure stably during the period up to the first is first, and after the gamma-linolenic acid-containing matrix is applied to the skin surface, the gamma-linolenic acid can be easily converted to the skin. It is a necessary condition that the molecular interaction is maintained such that it can be released toward the surface, and the component of the present invention must satisfy these two conditions.
[0004]
[Means for Solving the Problems]
From the viewpoint of molecular design, the target of the search for the matrix is set to be close to the fatty acid composition of human sebum. After application, crystals are released with weak intermolecular force to release gamma-linolenic acid on the skin surface. A mixture of myristic acid, palmitic acid, and stearic acid was selected because it is desirable that the saturated fatty acid formed be the main component, but these are crystalline solids at room temperature, and it is not easy to apply them to the skin surface as it is. Therefore, by mixing one-third to equivalent amounts of oleic acid to these mixed compositions, a matrix substrate that became liquid near human body temperature was obtained. Considering the availability as raw materials, the base material satisfying these conditions includes refined palm oil or refined horse oil. In the following examples, these refined palm oil or horse oil is used. ing. According to the present invention, the adjustment of the melting point of the mixed composition for use as a matrix is realized mainly by adjusting the amount of oleic acid added. Although addition of vitamin E is effective for stabilizing gamma-linolenic acid, the component according to the present invention uses an aluminum-coated tube as a container to avoid contact with oxygen and the effect of light. It is put into practical use with filling.
[0005]
[Action]
Conventionally, transdermal routes of replenishing medicinal ingredients include methyl salicylate preparations, nitroglycerin patches for heart disease, and nicotine patches for smoking cessation, all of which are transdermal. While the active ingredient that permeates through is absorbed by the capillaries, the gamma linolenic acid according to the present invention, its precursor linoleic acid, or a mixture thereof is contained in a matrix mainly containing saturated fatty acids. It only needs to be dissolved and applied to a predetermined part of the skin, then penetrate from the stratum corneum or epidermis to the dermis and stay there.
[0006]
BEST MODE FOR CARRYING OUT THE INVENTION
In order to carry out the present invention, a saturated fatty acid such as myristic acid, palmitic acid, stearic acid or a mixture thereof is used as a matrix of constituent components. These are added with oleic acid to adjust the melting point of the final composition to around 20 ° C. The molecular motion of gamma linolenic acid or linoleic acid placed in a solid state matrix is restricted, resulting in stabilization.
According to the present invention, the amount of gamma-linolenic acid as the main material is added in the range of 2 to 10 with respect to the amount of oleic acid used for adjusting the melting point of the matrix. When purified palm oil is used as a matrix, the amount of gamma linolenic acid is adjusted to be in the range of 2 to 10 with respect to the total amount of oleic acid contained in palm oil and oleic acid used for melting point adjustment, Linoleic acid up to the same amount as oleic acid can be added. Horse oil has a composition similar to human sebum, so when using it as a matrix, the amount of oleic acid contained in horse oil should be 10 and the amount of gamma-linolenic acid should be in the range of 2 to 10. . Normally, horse oil contains linoleic acid in an amount of 3 to 5 with respect to 10 oleic acid, which is useful for skin care and also contributes to lowering the melting point of the whole composition. Linoleic acid can be added until it is equivalent to oleic acid. The components prepared according to the present invention are filled into aluminum-coated tubes for practical use, and the antioxidant vitamin E is used in an amount of 0.5% to 20% based on the amount of gamma-linolenic acid. It is desirable that it be added at.
[0007]
【The invention's effect】
Apply the component according to the present invention to the upper arm skin, rub the surface sufficiently with a wrap film, and after 1 hour, collect the oil on the surface of the epidermis from this site using oil blotting paper. Then, the fatty acid component contained in the solution was analyzed by gas chromatography and compared with the fatty acid composition of the component before application. As a result, most of gamma-linolenic acid and part of linoleic acid were reduced. It showed that it was absorbed by the tissue.

Claims (1)

本発明は体内のガンマ・リノレン酸が不足することによっで発症する,とくに皮膚科領域の治療対象をはじめとするスキンケアの目的でガンマ・リノレン酸やガンマ・リノレン酸の前駆体であるリノール酸あるいはこれらの混合物を構成要素として経皮経路を利用して希望する部位近傍に補給する方法に関する.The present invention relates to gamma linolenic acid, a precursor of gamma linolenic acid, or linoleic acid, which is a precursor of gamma linolenic acid, which is caused by a lack of gamma linolenic acid in the body. Alternatively, the present invention relates to a method of using a mixture of these components as a component and supplying it near a desired site using a percutaneous route.
JP2003124569A 2003-03-25 2003-03-25 Method for supplying gamma-linolenic acid by transdermal pathway Pending JP2004292418A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003124569A JP2004292418A (en) 2003-03-25 2003-03-25 Method for supplying gamma-linolenic acid by transdermal pathway

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003124569A JP2004292418A (en) 2003-03-25 2003-03-25 Method for supplying gamma-linolenic acid by transdermal pathway

Publications (1)

Publication Number Publication Date
JP2004292418A true JP2004292418A (en) 2004-10-21

Family

ID=33410184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003124569A Pending JP2004292418A (en) 2003-03-25 2003-03-25 Method for supplying gamma-linolenic acid by transdermal pathway

Country Status (1)

Country Link
JP (1) JP2004292418A (en)

Similar Documents

Publication Publication Date Title
US6239177B1 (en) Tranilast-containing preparation for external application and method of producing the same
JP4825305B2 (en) Transdermal absorption preparation
TWI296531B (en) Transdermal adhesive preparations for topical administration of fentanyl
US20190298834A1 (en) Carrier composition
HU221598B (en) The use of glycerin in moderating transdermal drug delivery
ITMI961152A1 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
EP1928406A2 (en) Pharmaceutical compositions with melting point depressant agents and method of making same
CA2768457C (en) Pharmaceutical compositions
EP2516011B1 (en) Carrier composition for delivery of a biologically active compound
KR20070085772A (en) Instant patch for dermal drug delivery
TW201141522A (en) Carrier composition
TW201247218A (en) Suspension type topical formulations comprising cyclic depsipeptide
JPH1112177A (en) Stable aspirin-containing preparation for external use
JP2013515020A (en) Pharmaceutical composition or analogue comprising a solvent mixture and a vitamin D derivative
EA010871B1 (en) Transdermal formulations and methods for the treatment of thrombocythemia
KR20070059079A (en) Medicinal composition for percutaneous perospirone administration
TWI343259B (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JP2004292418A (en) Method for supplying gamma-linolenic acid by transdermal pathway
JP6625208B2 (en) Transdermal formulation
JP2008169155A (en) Penetration enhancer of medicine for nail and nail-treating agent for external application, containing the same
JP5619363B2 (en) Transdermal absorption enhancer, skin treatment preparation containing the same, and transdermal absorption preparation
JP2010202546A (en) Ointment preparation for treating atopic dermatitis
JP3841628B2 (en) Transdermal absorbent
ITMI20011321A1 (en) MICROEMULSION PHARMACEUTICAL COMPOSITION SUITABLE FOR TRANSMINISTRIC ADMINISTRATION OF APOMORPHINE USEFUL IN TREATMENT OF
WO2006057375A1 (en) Medicinal preparation for external use